The substantial data supporting platelet-rich plasma (PRP) therapy and exosomes for androgenic alopecia have yet to convince ...

The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' cancer therapy, chemically ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in ...

Incyte and Syndax Pharmaceutical said the Food and Drug Administration approved their graft disease treatment Niktimvo antibody in nine milligram and 22 milligram vial sizes.

The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with the greatest potential.

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...

Dr Tsun Sean Law details the ARISE trials and outlines other orthobiologic treatments currently available — but not yet ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

As previously announced on December 13, Diamyd Medical had held a positive in-person meeting with the FDA. Following the meeting, Diamyd Medical has now received the final minutes. The FDA provided ...

Three Georgia companies and their principals have been banned from continuing their "bogus claims" that their stem cell ...